Corbus Pharmaceuticals Holdings Shares Are Trading Lower Amid Sympathy With Novo Nordisk After the Company Reported Results From Its Phase2a Trial of Monlunabant in Obesity. Also, Wedbush Maintained an Outperform Rating on the Stock but Lowered Its...

Benzinga · Sep 21 00:29

Corbus Pharmaceuticals Holdings Shares Are Trading Lower Amid Sympathy With Novo Nordisk After the Company Reported Results From Its Phase2a Trial of Monlunabant in Obesity. Also, Wedbush Maintained an Outperform Rating on the Stock but Lowered Its Price Target From $85 to $51.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

Corbus Pharmaceuticals Holdings Shares Are Trading Lower Amid Sympathy With Novo Nordisk After the Company Reported Results From Its Phase2a Trial of Monlunabant in Obesity. Also, Wedbush Maintained an Outperform Rating on the Stock but Lowered Its...

Corbus Pharmaceuticals Holdings Shares Are Trading Lower Amid Sympathy With Novo Nordisk After the Company Reported Results From Its Phase2a Trial of Monlunabant in Obesity. Also, Wedbush Maintained an Outperform Rating on the Stock but Lowered Its Price Target From $85 to $51.

Risk Disclaimer